Back to Trials
NCT07059884NARecruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

Alliance for Clinical Trials in Oncology

Start Date

2/11/2026

Completion Date

8/31/2027

Summary

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.

Detailed Description

PRIMARY OBJECTIVES: I. To establish the feasibility of implementing a virtual exercise intervention trial in a diverse cohort of cancer patients undergoing chemotherapy. SECONDARY OBJECTIVE: I. To establish feasibility of enrolling and retaining a diverse patient population. EXPLORATORY OBJECTIVES: I. Evaluate changes in 6 Minute Walk Test (6MWT) distance in the study population between baseline and the post-chemotherapy time point. II. Evaluate changes in grip strength in the study population between baseline and the post-intervention time point. III. Evaluate objective (accelerometer) and self-reported changes (7-Day Physical Activity Recall Interview) in physical activity in the study population between baseline and the post-intervention time point. IV. Explore the relationship between the predicted 6MWT and the baseline 6MWT. V. Explore changes in patient reported outcomes between baseline, end of intervention, and 3-months post intervention in the study population. VI. Explore employment status over time in the study population. VII. Explore differences intervention adherence and attrition by: 1. Duration of chemotherapy regimen (12 weeks or less vs more than 12 weeks) 2. Administration of chemotherapy in adjuvant vs neoadjuvant setting 3. Administration of cytotoxic chemotherapy alone vs in combination with radiation 4. Administration of cytotoxic chemotherapy alone vs in combination with immunotherapy or other targeted agent (monoclonal antibody, small molecule inhibitor, etc) OUTLINE: Patients complete supervised TH exercise sessions consisting of aerobic exercise over 20 minutes and progressive resistance exercise twice a week (BIW) and complete unsupervised aerobic exercise for a total of 50 minutes per week until the end of standard of care (SOC) chemotherapy or up to a total of 6 months, whichever comes first, in the absence of disease progression or unacceptable toxicity. Patients also receive a stationary bike, workbook, gloves, and resistance bands on study and wear an accelerometer throughout the study. After completion of study intervention, patients are followed up at 4 weeks and 3 months.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon/rectum, endometrium, esophagus, gallbladder, head/neck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed) * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions * CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder: \* Providing clinical care for participating patients on this study * CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English Exclusion Criteria: \-

Interventions

OTHER

Exercise intervention

OTHER

Telemedicine

OTHER

Aerobic Exercise Intervention

OTHER

Exercise Intervention

PROCEDURE

Accelerometry

OTHER

Questionnaire Administration

OTHER

Interview

OTHER

Electronic Health Record Review

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Localized Malignant Solid NeoplasmAnal CancerBladder (Urothelial, Transitional Cell) CancerBreast CancerCervical CancerColon CancerEndometrial CancerEsophageal CancerGall Bladder CancerGastric CancerKidney CancerLiver CancerLung CancerHead and Neck CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSarcoma

Locations

Kaiser Permanente Dublin

Dublin, California 94568

United States

Kaiser Permanente-Fremont

Fremont, California 94538

United States

Kaiser Permanente Fresno Orchard Plaza

Fresno, California 93720

United States

Kaiser Permanente-Modesto

Modesto, California 95356

United States

Kaiser Permanente-Oakland

Oakland, California 94611

United States

Kaiser Permanente-South Sacramento

Sacramento, California 95823

United States

Kaiser Permanente-Santa Teresa-San Jose

San Jose, California 95119

United States

Kaiser San Rafael-Gallinas

San Rafael, California 94903

United States

Kaiser Permanente-Vallejo

Vallejo, California 94589

United States

Dana-Farber Cancer Institute

Boston, Massachusetts 02215

United States

Novant Health Cancer Institute - Kernersville

Kernersville, North Carolina 27284

United States

Novant Health Cancer Institute - Mount Airy

Mount Airy, North Carolina 27030

United States

Novant Health Forsyth Medical Center

Winston-Salem, North Carolina 27103

United States

UPMC Hillman Cancer Center at Butler Health System

Butler, Pennsylvania 16001

United States

IRMC Cancer Center

Indiana, Pennsylvania 15701

United States

UPMC Hillman Cancer Center - New Castle

New Castle, Pennsylvania 16105

United States

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania 15232

United States

UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania 16346

United States